The city will provide the new COVID-19 Bamlanivimab treatment, starting this week, to avoid hospitalizations.
El Paso was selected to provide this treatment developed by Eli Lilly due to the high number of positive COVID-19 cases and hospitalizations. El Paso received a limited number of doses of this new infusion therapy.
“We are grateful to have been selected to pilot a noble treatment program aimed at preventing a higher number of hospitalizations among our most vulnerable loved ones, thereby improving their outcomes when infected with COVID-19,” said Dr Hector Ocaranza, City County Local Health Authority. in a press release.
The FDA has cleared the emergency use of Bamlanivimab, a drug used for the treatment of COVID-19 in patients who meet the following criteria:
- COVID-19 positive
- Adults and non-hospitalized adolescents 12 years of age and over
- Mild to moderate symptoms
- Weigh 88 pounds or more
- Underlying health conditions
- High risk of developing severe symptoms of COVID-19
Bamlanivimab is not authorized for patients already in hospital or requiring oxygen therapy due to COVID-19.
Patients eligible for treatment will receive a single intravenous (IV) dose lasting approximately 1 hour. Patients will need to wait an additional hour to monitor the reaction to treatment.
What is bamlanivimab? What is a monoclonal antibody?
According to the FDA, Bamlanivimab is a monoclonal antibody, molecules produced in the laboratory designed to serve as surrogate antibodies that can restore, enhance, or mimic the immune system’s attack on cells.
Bamlanivimab is designed to block viral uptake and entry into human cells, thereby neutralizing the virus. It is designed to limit viral replication and may be effective for the treatment of COVID-19 in patients who are at high risk of developing to severe COVID-19 and / or of being hospitalized.
When should Bamlanivimab be given to a patient?
According to the FDA, it is recommended that Bamlanivimab be administered as soon as possible after a positive viral test for SARS-CoV-2 and within 10 days of onset of symptoms. Bamlanivimab is given as a single 700 mg dose by IV infusion over 60 minutes.
Is Bamlanivimab FDA Approved to Treat COVID-19?
According to the FDA, Bamlanivimab is an investigational drug. It is not currently approved by the FDA to treat any diseases or conditions, including COVID-19.
However, upon issuance of the Emergency Use Authorization (EUA), Bamlanivimab is authorized for emergency use for the treatment of mild to moderate COVID-19 in adults and pediatric patients with positive results. 12-year-old SARS-CoV-2 direct viral tests. aged at least 40 kg and who are at high risk of progressing to severe COVID-19 and / or hospitalization.
What is an Emergency Use Authorization (EUA)?
The FDA may authorize an unapproved product or unapproved uses of an approved product for emergency use. In issuing an EUA, the FDA must determine, among other things, that the product may be effective in diagnosing, treating or preventing a serious or fatal disease or condition caused by a chemical, biological, radiological or nuclear agent. Emergency use authorization is not the same as FDA approval or clearance.